丝裂原活化的蛋白激酶:一个治疗病理性痛潜在的药物新靶点  

Mitogen-activated proteins kinases:an emerging therapeutic target for pathological pain

作　　者：张颜波[1] 吕国蔚[2] 

机构地区：[1]泰山医学院附属医院神经内科,山东泰山271000 [2]首都医科大学低氧医学研究所,北京100069

出　　处：《中国药理学通报》2009年第7期848-851,共4页Chinese Pharmacological Bulletin

基　　金：北京市自然科学基金资助项目(No7962009)

摘　　要：病理性痛(pathological pain)是临床上常见的疼痛,通常分为炎性痛(inflammatory pain)和神经病理性痛(neuro-pathic pain),具有痛觉过敏和痛觉异常等疼痛神经可塑性特点;丝裂原活化的蛋白激酶(mitogen-activated proteins kinases,MAPKs)作为一种关键细胞信号分子,包括细胞外信号调节激酶(ERK)、p38和c-Jun氨基末端激酶(JNK)3条主要激活通路,在病理性痛觉信号转导和神经可塑性调控中起重要作用。在不同动物模型中,抑制MAPKs信号通路,可明显减轻炎症痛和神经病理性痛,这为MAPKs抑制剂开发成为治疗病理性痛的药物提供了可能,MAPKs已成为治疗病理性痛药物作用的一个重要的潜在的靶点。Pathological pain or clinical pain is caused by tissue and nerve injuries, and is usually chronic and mainly divided into inflammatory pain and neuropathic pain. Pathological pain is typically characterized by hyperalgesia （increased responsive- ness to noxious stimuli） and allodynia （painful responses to normally innocuous stimuli）. The MAPKs are a family of evolutionally conserved molecules that play a critical role in cell signaling, consisting of extracellular signal-regulated kinase （ERK）, p38, and c-Jun N-terminal kinase （JNK） , which play an important role in neural plasticity of pathological pain. Inhibition of MAPKs alleviates inflammatory pain and neuropathic pain in different animal models. It is very important to study the inhibition of MAPKs as a therapeutic approach to treating pathological pain. All the studies suggest that MAPKs is a promising therapeutic target for pathological pain.

关 键 词：MAPKS 病理性痛 炎症痛 神经病理性痛 MAPKs抑制剂 

分 类 号：R-05[医药卫生] R345.57